The startup develops biodegradable skin regenerating sheets specifically for patients undergoing breast tissue removal due to cancer, significantly lowering reconstruction surgery costs. By providing individualized treatments, the company enables faster recovery and safer surgical outcomes for these patients.
Funding
Funding not disclosed
Founders
Product
Problem
Patients undergoing breast tissue removal due to cancer often require reconstructive surgery, which can be costly and involve extended recovery times. Current reconstructive methods may not always provide individualized treatments, potentially leading to less than optimal surgical outcomes.
Solution
PLCOskin develops biodegradable skin-regenerating sheets designed to reduce the costs associated with reconstructive surgery following breast tissue removal. Their TissueDerm products aim to provide individualized treatments that promote faster recovery and improved surgical outcomes. The company leverages its expertise in regenerative medicine and biotechnology to create solutions that enhance the quality of life for patients. PLCOskin's offerings include TissueDerm, TissueDerm Orbit, TissueDerm Graft, and Medi A Derm, each tailored for specific applications. By focusing on user suitability and continuous research and development, PLCOskin strives to be a leader in the bio-medical regeneration industry.
Target Audience
The primary target audience includes patients undergoing breast tissue removal and reconstructive surgery, as well as surgeons and medical professionals seeking advanced solutions for tissue regeneration.
Features
- Biodegradable skin regenerating sheets for tissue reconstruction.
- Individualized treatment options for various surgical needs.
- TissueDerm product line for different applications.
- Focus on faster recovery and safer surgical outcomes.
- Patented technology (e.g., Patent Registration No. 10-2364686).
- Research-backed with SCI publications on nanostructure surface-guided lipogenesis and anti-aging effects of nanovesicles.